These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 30783954)

  • 21. Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segment-elevation myocardial infarction.
    Alexopoulos D; Xanthopoulou I; Gkizas V; Kassimis G; Theodoropoulos KC; Makris G; Koutsogiannis N; Damelou A; Tsigkas G; Davlouros P; Hahalis G
    Circ Cardiovasc Interv; 2012 Dec; 5(6):797-804. PubMed ID: 23169985
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sex Differences in the Clinical Impact of High Platelet Reactivity After Percutaneous Coronary Intervention With Drug-Eluting Stents: Results From the ADAPT-DES Study (Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents).
    Yu J; Mehran R; Baber U; Ooi SY; Witzenbichler B; Weisz G; Rinaldi MJ; Neumann FJ; Metzger DC; Henry TD; Cox DA; Duffy PL; Mazzaferri EL; Brodie BR; Stuckey TD; Maehara A; Xu K; Ben-Yehuda O; Kirtane AJ; Stone GW
    Circ Cardiovasc Interv; 2017 Feb; 10(2):. PubMed ID: 28193677
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prevalence of high on-treatment (aspirin and clopidogrel) platelet reactivity in patients with critical limb ischemia.
    Clavijo LC; Al-Asady N; Dhillon A; Matthews RV; Caro J; Tun H; Rowe V; Shavelle DM
    Cardiovasc Revasc Med; 2018 Jul; 19(5 Pt A):516-520. PubMed ID: 29221961
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Routine assessment of on-clopidogrel platelet reactivity and gene polymorphisms in predicting clinical outcome following drug-eluting stent implantation in patients with stable coronary artery disease.
    Viviani Anselmi C; Briguori C; Roncarati R; Papa L; Visconti G; Focaccio A; De Micco F; Latronico MV; Pagnotta P; Condorelli G
    JACC Cardiovasc Interv; 2013 Nov; 6(11):1166-75. PubMed ID: 24262617
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The expression profile of platelet-derived miRNA in coronary artery disease patients with clopidogrel resistance.
    Lin S; Xu X; Hu H; Cheng J; Chen R; Hu Y; Chen X
    Pharmacol Res Perspect; 2021 Apr; 9(2):e00751. PubMed ID: 33724726
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of Aspirin and Clopidogrel Hyporesponsiveness in Patients Treated With Drug-Eluting Stents: 2-Year Results of a Prospective, Multicenter Registry Study.
    Stuckey TD; Kirtane AJ; Brodie BR; Witzenbichler B; Litherland C; Weisz G; Rinaldi MJ; Neumann FJ; Metzger DC; Henry TD; Cox DA; Duffy PL; Mazzaferri EL; Gurbel PA; Mehran R; Généreux P; Ben-Yehuda O; Simonton CA; Stone GW;
    JACC Cardiovasc Interv; 2017 Aug; 10(16):1607-1617. PubMed ID: 28780034
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ticagrelor downregulates the expression of proatherogenic and proinflammatory miR125-b compared to clopidogrel: A randomized, controlled trial.
    Gasecka A; Błażejowska E; Pluta K; Gajewska M; Rogula S; Filipiak KJ; Kochman J; Siller-Matula JM; Postuła M; Eyileten C
    Int J Cardiol; 2024 Jul; 406():132073. PubMed ID: 38643804
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacodynamic effect of switching therapy in patients with high on-treatment platelet reactivity and genotype variation with high clopidogrel Dose versus prasugrel: the RESET GENE trial.
    Sardella G; Calcagno S; Mancone M; Palmirotta R; Lucisano L; Canali E; Stio RE; Pennacchi M; Di Roma A; Benedetti G; Guadagni F; Biondi-Zoccai G; Fedele F
    Circ Cardiovasc Interv; 2012 Oct; 5(5):698-704. PubMed ID: 23048056
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clopidogrel response variability is associated with endothelial dysfunction in coronary artery disease patients receiving dual antiplatelet therapy.
    Siasos G; Oikonomou E; Zaromitidou M; Kioufis S; Kokkou E; Mourouzis K; Vlasis K; Vavuranakis M; Stone PH; Papavassiliou AG; Tousoulis D
    Atherosclerosis; 2015 Sep; 242(1):102-8. PubMed ID: 26188531
    [TBL] [Abstract][Full Text] [Related]  

  • 30. High-dose atorvastatin on the pharmacodynamic effects of double-dose clopidogrel in patients undergoing percutaneous coronary interventions: The ACHIDO (Atorvastatin and Clopidogrel HIgh DOse in stable patients with residual high platelet activity) study.
    Leoncini M; Toso A; Maioli M; Angiolillo DJ; Giusti B; Marcucci R; Abbate R; Bellandi F
    JACC Cardiovasc Interv; 2013 Feb; 6(2):169-79. PubMed ID: 23428009
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evolving role of platelet function testing in coronary artery interventions.
    Sharma RK; Voelker DJ; Sharma R; Reddy HK; Dod H; Marsh JD
    Vasc Health Risk Manag; 2012; 8():65-75. PubMed ID: 22371653
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Influence of
    Liu YL; Hu XL; Song PY; Li H; Li MP; Du YX; Li MY; Ma QL; Peng LM; Song MY; Chen XP
    J Am Heart Assoc; 2021 Nov; 10(21):e021129. PubMed ID: 34713722
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A comparative cohort study on personalised antiplatelet therapy in PCI-treated patients with high on-clopidogrel platelet reactivity. Results of the ISAR-HPR registry.
    Mayer K; Schulz S; Bernlochner I; Morath T; Braun S; Hausleiter J; Massberg S; Schunkert H; Laugwitz KL; Kastrati A; Sibbing D
    Thromb Haemost; 2014 Aug; 112(2):342-51. PubMed ID: 24718389
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tailored antiplatelet therapy to improve prognosis in patients exhibiting clopidogrel low-response prior to percutaneous coronary intervention for stable angina or non-ST elevation acute coronary syndrome.
    Paarup Dridi N; Johansson PI; Lønborg JT; Clemmensen P; Radu MD; Qayyum A; Pedersen F; Kollslid R; Helqvist S; Saunamäki K; Kelbæk H; Jørgensen E; Engstrøm T; Holmvang L
    Platelets; 2015; 26(6):521-9. PubMed ID: 25166751
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacodynamic Effects of Switching From Prasugrel to Ticagrelor: Results of the Prospective, Randomized SWAP-3 Study.
    Franchi F; Faz GT; Rollini F; Park Y; Cho JR; Thano E; Hu J; Kureti M; Aggarwal N; Durairaj A; Been L; Zenni MM; Guzman LA; Suryadevara S; Antoun P; Bass TA; Angiolillo DJ
    JACC Cardiovasc Interv; 2016 Jun; 9(11):1089-98. PubMed ID: 27013060
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of Reticulated Platelets on the Antiplatelet Effect of the Intravenous P2Y12-Receptor Inhibitor Cangrelor.
    Stratz C; Nührenberg T; Valina CM; Löffelhardt N; Mashayekhi K; Ferenc M; Trenk D; Neumann FJ; Hochholzer W
    Thromb Haemost; 2018 Feb; 118(2):362-368. PubMed ID: 29443372
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of Modifying Antiplatelet Treatment to Ticagrelor in High-Risk Coronary Patients With Low Response to Clopidogrel (MATTIS).
    Musallam A; Orvin K; Perl L; Mosseri M; Arbel Y; Roguin A; Lev EI
    Can J Cardiol; 2016 Oct; 32(10):1246.e13-1246.e19. PubMed ID: 26971236
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Advocating cardiovascular precision medicine with P2Y12 receptor inhibitors.
    Winter MP; Grove EL; De Caterina R; Gorog DA; Ahrens I; Geisler T; Gurbel PA; Tantry U; Navarese EP; Siller-Matula JM
    Eur Heart J Cardiovasc Pharmacother; 2017 Oct; 3(4):221-234. PubMed ID: 28204303
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of initial clinical presentation on clopidogrel low response.
    Landel JB; Bauters A; Delhaye C; Bonello L; Sudre A; Susen S; Bauters C; Lablanche JM; Lemesle G
    Arch Cardiovasc Dis; 2013 Nov; 106(11):593-600. PubMed ID: 24070598
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The association of P2Y
    Haller PM; Stojkovic S; Piackova E; Andric T; Wisgrill L; Spittler A; Wojta J; Huber K; Jäger B
    Platelets; 2020 May; 31(4):497-504. PubMed ID: 31389740
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.